TVT abbrevo: a retrospecti study of efficacy and outcomes at 5 years follow up at a tertiary centre in Singapore





SQ Tan, HC Han

Department of Urogynaecology, KK Women's and Children's Hospital, Singapore

Introduction

Midurethral sling system is the most common surgical treatment for female stress incontinence. TVT abbrevo is a 12cm transobturator midurethral sling with the postulated advantage of reduced post-operative groin and thigh pain, while maintaining similar efficacy to its predecessors (TVT-O). We aim to assess the efficacy of TVT abbrevo, and the outcomes at 5 years follow-up at our centre.

Methods

A retrospective study was conducted on all patients who underwent TVT abbrevo only from 1 September 2011 – 30 September 2013. Patients were reviewed for satisfaction, recurrence of symptoms, and post-operative side effects at 1 month, 6 month, 12 months and yearly till 60 months.

A total of 93 patients underwent TVT abbrevo during the 25 months. 91.4% had previous vaginal or instrumental deliveries. The average BMI was 26.8 kg/m². The patient characteristics of our study are summarised in Table 1.

Parameters	n=93
Age (years) (Mean ± SD; range)	49.4 ± 8.7 (32 – 73)
Parity (Mean ± SD; range)	$2.3 \pm 0.9 (0 - 6)$
Nulliparous (n. %)	2 (2.2)
Vaginal Delivery (n. %)	81 (87.1)
Pure Instrumental Delivery (n. %)	4 (4.3)
Vaginal / Instrumental Delivery (n. %)	85 (91.4)
LSCS only (n. %)	6 (6.5)
BMI (kg/m^2) $(n = 90)$ (Mean \pm SD;	26.8 ± 4.4 (17.7 – 43.6)
range)	
Menopause (n. %)	23 (24.7)
HRT (n; %)	0
Previous Surgery for SUI (n. %)	0
Previous Surgery for POP (n; %)	1 (1.1)
	• 1 underwent anterior repair
Previous Hysterectomy (n. %)	4 (4.3)
(a) Laparoscopic	3
(b) Abdominal	1
Physiotherapy tried (n. %)	15 (16.1)

Table 1: Patient demographic profile

46.2% had concomitant urinary urge incontinence. 100% had demonstrable stress incontinence, with an average of 12.9 gm of urine leaked on erect stress test. The pre-operative symptoms are summarised in Table 2.

Parameters	n=93
Stress Urinary Incontinence (SUI) (n. %)	93 (100)
Urgency/Urge Incontinence (n. %)	43 (46.2)
Frequency/nocturia (n. %)	24 (25.8)
Voiding difficulty (n. %)	19 (20.4)
Lump (n: %)	9 (9.7)
EST/supine cough stress test (demonstrable) (n = 92) (n: %)	61 (65.6)
EST/supine cough stress test (demonstrable) (g) $(n = 60)$ (Mean \pm SD; range)	12.9 ± 19.8 (0.2 – 103)

Table 2: Summary of pre-operative symptoms

The mean operating duration was 14.3 minutes. There were 3 cases of bladder perforation and 4 cases of vaginal perforation. The mean hospitalization stay was 1.1 days, and mean catheterization duration was 0.8 days. No patient had prolonged catheterization (> 7 days) post-operatively.

Parameters	n=93			
Duration (min) (Mean ± SD; range)	14.3 ± 6.3 (5 – 40)			
Anesthesia (n. %)				
(a) GA	69 (74.2)			
(b) RA	24 (25.8)			
Bladder perforation (n. %)	3 (3.2)			
Vaginal perforation (n; %)	4 (4.3)			
<u> </u>	- 17			
Significant blood loss >100 (n. %)	0			
Estimated blood loss (ml) (n = 85) (Mean ± SD; range)	$11.1 \pm 11.2 (0 - 50)$			
Hospital stay (day) (Mean ± SD; range)	$1.1 \pm 0.5 (0.5 - 3)$			
Catheterization (day) (Mean ± SD; range)	$0.8 \pm 0.6 (0 - 3.5)$			
Prolonged catheter ≥ 7 days (n; %)	0			
Nil Catheterization (n. %)	27 (29.0)			
Fever (n; %)	2 (2.2)			
UTI within 1 month of operation needing Abx (n. %)	2 (2.2)			

Table 3: Operative details

At time of writing, a total of 87 patients completed their 48 months follow up, and 45 patients completed their 60 month follow up. Three patients had wound pain at 6 months, which resolved at 12 months.

Post TVT abbrevo at 6 months, only one patient had demonstrable leak of urine. Three patients had mesh extrusion to the vaginal wall at 6 months, and one patient had mesh extrusion at 12 months. Objective cure rate was up to 100% at 36, 48 and 60 months. Patient satisfaction persistently achieved above 95% across all 5 years. The outcomes are summarised in Table 4.

	6 months (n=93)	1 year (n=93)	2 years (n=93)	3 years (n=93)	4 years (n=93)	5 years (n=53)
Follow-up (n; %)	89 (95.7)*	88 (94.6) ^b	88 (94.6)¢	88 (94.6)4	87 (93.5)¢	45 (84.9)f
SUI (n: %): Cured Improved No Change	82 (92.1) 6 (6.7) 1 (1.1)	82 (93.2) 3 (3.4) 3 (3.4)	81 (92.0) 5 (5.7) 2 (2.3)	80 (90.9) 6 (6.8) 2 (2.3)	79 (90.8) 6 (6.9) 2 (2.8)	40 (88.9) 4 (8.9) 1 (2.2)
U/UI (n: %): Cured Improved No Change New Onset	n = 42 28 (66.7) 12 (28.5) 2 (4.8) 0	n = 41 25 (61.0) 14 (34.1) 2 (4.9) 0	n = 42 23 (54.8) 16 (38.1) 2 (4.8) 1 (2.3)	n = 42 27 (64.3) 14 (33.3) 1 (2.4) 0	n = 42 26 (61.9) 15 (35.7) 1 (2.4) 0	n = 23 17 (73.9) 5 (21.7) 1 (4.3)
Wound pain (n: %)	3 (3.4)	0	0	0	0	0
EST/supine cough stress test (demonstrable) (n; %)	1 (1.1)	2 (2.3)	1 (1.1)	0	0	0
Mesh extrusion to vagina wall (n; %)	3 (3.4)	1 (1.1)	0	0	0	0
Patient satisfaction (n; %)	88 (98.9)	85 (96.6)	85 (96.6)	84 (95.5)	83 (95.4)	n = 44 42 (95.5)
Subjective cure rate (n. %)	82 (92.1)	82 (93.2)	81 (92.0)	80 (90.9)	79 (90.8)	40 (88.9)
Objective cure rate (n; %)	88 (98.9)	86 (97.7)	87 (98.9)	88 (100)	87 (100)	45 (100)

Table 4: Outcome of patients who have undergone TVT abbrevo

Conclusion

TVT abbrevo is an excellent alternative for female stress incontinence.

PATIENTS. AT THE HE RT OF ALL WE DO.



















